Session: 253. HAI: *C. difficile* - Surveillance
Saturday, October 5, 2019: 12:15 PM

Background. *Clostridioides difficile* infection (CDI) is the most common pathogen to cause healthcare-associated infections. Unlike some other bacterial pathogens antimicrobial treatment is seldom based on culture with susceptibility testing with infrequent surveillance for antimicrobial resistance. We have evaluated healthcare-onset CDI (HO-CDI) for both transmission and antimicrobial resistance emergence.

Methods. We identified cases of HO-CDI diagnosed by PCR within a 3 month period (October 1/2018–December 31/2018) at University of Virginia Health System with overlapping stays in the same inpatient units with other HO-CDI. Chart review of all cases was performed. *C. difficile* was cultured from stool, then DNA was extracted and underwent sequencing on Illumina Miseq platform. Antimicrobial resistance genes were screened using NCBI's AMRFinder tool from the *de-novo* assembled contigs using SPAdes. All the *C. difficile* isolates underwent antibiotic susceptibility testing.

Results. Eleven patients were identified with overlapping stays from 5 units. Mean age was 64 years and 63.6% were female. 36.3% of cases were severe CDI with one case of fulminant CDI. There was one recurrence within 90 days (9.1%). Patients were treated with PO vancomycin (72.7%) or IV metronidazole and PO vancomycin (27.3%), none were treated with metronidazole alone. None of the hospital strains were genetically related. There were two isolates with binary toxin gene (*cdtB*), one ribotype 027 (CD196) and one ribotype 078 (M120). Ninety-one percent of isolates had *vanG*-like gene cluster and *vanZ1* originally identified in *Enterococcus* sp. *erm*(B), *tet*(M), and *cfr*(C) genes were also detected in several strains. All isolates were susceptible to vancomycin, metronidazole, and tigecycline. There was one strain with moxifloxacin resistance associated with the presence of *erm*(B) gene. None of the isolates were susceptible to clindamycin.

Conclusion. There were no widely circulating clones or direct transmissions found in this small sample of HO-CDI cases at our hospital. Like others have we demonstrate carriage of many *vanG/Z* genes without conferring phenotypic resistance to vancomycin. The origin and function of Van genes in *C. difficile* could be an area of future research.

Disclosures. **All authors:** No reported disclosures.

2430. Comorbidity and Severity of Illness Risk Adjustment for Hospital-Onset Clostridioides difficile Infection

Stephanie Cabral, BS[1]; Gita Nadimpalli, MD MPH[2]; Kerri Thom, MD, MS[1]; Surbhi Leekha, MBBS, MPH[3]; Lisa Harris, MA[3]; Natalia Blanco Herrera, MPH, PhD[1]; Anthony Harris, MD, MPH[4]; [1]University of Maryland School of Medicine, Baltimore, Maryland; [2]University of Maryland, Baltimore, Maryland; [3]University of Maryland Dept of Epidemiology and Public Health, Baltimore, Maryland; [4]university of maryland school of medicine, Baltimore, Maryland

Session: 253. HAI: *C. difficile* - Surveillance
Saturday, October 5, 2019: 12:15 PM

Background. Hospital-onset *C. difficile* infection (HO-CDI) rates are publicly reported. However, patient-level risk factors are not included in the current risk adjustment methodology, and the knowledge as to which risk factors to include is incomplete. This study aimed to determine whether electronically-available comorbidities and laboratory indicators of severity of illness are risk factors for HO-CDI.

Methods. We performed a retrospective cohort study of all adult patients admitted to three hospitals (one academic, two community) in Baltimore, Maryland between January 1, 2016 and January 1, 2018. Information extracted from electronic medical records included demographics, ICD-10 codes, laboratory results within 24 hours of admission (i.e., hematocrit, hemoglobin, platelet count, leukocytes, BUN, CO2, creatinine, glucose, sodium, and potassium), medication administration (i.e., antibiotic and antacid use), and *C. difficile* test result. Comorbid conditions were assessed by the Elixhauser Comorbidity Index components. HO-CDI was defined by positive laboratory test > 3 days after admission. Potential risk factors for HO-CDI were assessed using bivariate log binomial regression. Multivariable log binomial regression was conducted using significant ($P < 0.1$) covariates.

Results. At hospital 1 (academic), 314 of the 48,057 (0.65%) eligible patient admissions had HO- CDI; 41 of the 8,791 (0.47%) and 75 of the 29,211 (0.26%) of patient admissions at community hospitals 2 and 3, respectively, had HO-CDI. In multivariable analysis, Elixhauser Score was a significant risk factor for HO-CDI at all hospitals when controlling for antibiotic and antacid use; for every one-point increase in Elixhauser Score, there was an increased risk of HO-CDI of 1.27 (95% CI: 1.21, 1.32) at hospital 1, 1.38 (95% CI: 1.24, 1.54) at hospital 2, and 1.28 (95% CI: 1.10, 1.31) at hospital 3. Table 1 shows significant risk factors for HO-CDI for each hospital. When individual comorbidities were assessed in the regression analysis, fluid and electrolyte disorders were a significant risk factor for HO-CDI for all hospitals.

Conclusion. Laboratory values upon admission and electronically available patient comorbidities are important risk factors for HO-CDI and should be considered for future risk adjustment.

Table 1. Multivariable log binomial regression models for risk adjustment of HO-CDI for individual hospitals stepwise regression **(Model 1)**

Hospital 1				Hospital 2				Hospital 3			
Characteristics	Risk Ratio	95% Confidence Interval	p value	Characteristics	Risk Ratio	95% Confidence Interval	p value	Characteristics	Risk Ratio	95% Confidence Interval	p value
Antibiotic Use	3.15	(2.20, 4.50)	< 0.001	Antibiotic Use	4.37	(1.76, 10.86)	0.002	Gender (female)	0.64	(0.40, 1.04)	0.07
H2 Blocker Use	1.52	(1.20, 1.91)	< 0.001	Elixhauser Score	1.38	(1.24, 1.54)	< 0.001	Antibiotic use	4.86	(2.27, 10.39)	<.001
PPI Use	1.55	(1.21, 1.97)	< 0.001	Abnormal Leukocytes	2.78	(1.47, 5.24)	0.002	H2 receptor blocker use	2.56	(1.56,4.20)	< 0.001
Elixhauser Score	1.27	(1.21, 1.32)	< 0.001					PPI use	1.61	(1.00, 2.61)	0.051
Abnormal Leukocytes	1.37	(1.09, 1.73)	0.008					Total Elixhauser	1.28	(1.17, 1.39)	<.001
								Abnormal Creatinine	2.08	(1.24, 3.47)	0.005

Disclosures. **All authors:** No reported disclosures.

2431. When More is Less – Recognizing More Community-onset *Clostridium difficile* Infections Helps to Dramatically Lower C diff Standardized Infection Ratio (SIR)

JORGE P. PARADA, MD, MPH[1]; Melissa Green[2]; Dominique Wright, MPH[1]; Deborah Parilla, RN, BSN[1]; Heather Hedlund, RN[1]; Amanda Harrington, PhD[3]; Kevin R Smith, MD[1]; [1]Loyola University Medical Center, Maywood, Illinois; [2]Loyola Univerity Medical Center, MAYWOOD, Illinois; [3]Loyola University & Medical Center, Maywood, Illinois

Session: 253. HAI: *C. difficile* - Surveillance
Saturday, October 5, 2019: 12:15 PM

Background. It is essential to recognize the true burden of community-onset (CO) *Clostridium difficile* infection (CDI) in hospital, not only because it prevents late recognition of CO CDI as being classified as a hospital-onset (HO) event, but also to assure appropriate contact precautions and therapeutic measures are deployed in a timely fashion. We recognized that our timely diagnosis of CO-CDI was suboptimal and sought to improve early recognition of CO-CDI.

Methods. We developed an automated daily report for all patients during their first 3 days of hospitalization who had loose stools documented in the nursing flow sheets and no stool sample sent to the lab. This report was automatically pushed out to the unit nurse managers, as well as reviewed by the infection preventionists (IP). Nurse managers alerted staff to acquire a stool sample to send to the lab. If stool testing still was not sent at the time of IP review of these symptomatic cases, then the IP called the nurse caring for the patient to encourage that a stool sample be sent ASAP and before the third hospital day was completed.

Results. We increased early appropriate stool testing for patients with documented loose stools during the first 3 days of hospitalization. Improved early diagnosis and better lab stewardship was associated with a marked increase in CO-CDI (15.6/month in 2015 vs 58.7/month in the last year), as well as a decrease in HO-CDI (22.8/month in 2015 vs 7.4/month last year) (Figure 1). In turn, we saw a remarkable drop in our CDI SIR (2 year pre-intervention SIR = 1.49 vs post-intervention SIR for the last 1.5 years = 0.41) (Figure 2).

Conclusion. After several years of our CDI SIR remaining stubbornly around 1.5, we developed a system of enhanced recognition of patients who had loose stools early in their hospitalization. This aided in better recognition of CDI present on admission, substantially increasing our detection of CO-CDI. We also noted decreases in HO-CDI, presumably secondary to no longer diagnosing patients later in their hospitalization as HO-CDI cases who actually had been admitted with CO-CDI. Better early recognition and isolation of patients with CDI also helped to decrease inadvertent *C. difficile* transmission in hospital, contributing to decreases in HO-CDI. In turn, we noted a remarkable decrease in our CDI SIR.

Figure 1



Figure 2



Disclosures. **All authors:** No reported disclosures.